Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, Dr. Bertozzi will serve on the company’s Science and Technology Committee as well as the Ethics and Compliance Committee. Her return reinforces Lilly’s commitment to scientific excellence and ethical leadership as it advances new therapeutic innovations.
Leadership Remarks
David A. Ricks, chair and CEO of Eli Lilly and Company, welcomed Dr. Bertozzi back to the board and highlighted her profound influence on the field of targeted medicine. He emphasized that her Nobel Prize winning research has transformed scientific approaches to drug development, particularly within oncology. Ricks noted that her insights will play an important role as Lilly continues to pursue breakthroughs across oncology, immunology, and other critical therapeutic areas.
Academic and Scientific Background
Dr. Carolyn Bertozzi holds several distinguished positions at Stanford University, where she serves as the Baker Family director of Sarafan ChEM-H and as the Anne T. and Robert M. Bass professor in the School of Humanities and Sciences. She is also a professor, by courtesy, of Chemical and Systems Biology and of Radiology. In addition to her academic appointments, she is an Investigator of the Howard Hughes Medical Institute, reflecting her significant contributions to chemical biology and translational research.
Her scientific achievements have been recognized with numerous honors, including election to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Her pioneering work in bioorthogonal chemistry earned her the Nobel Prize in Chemistry and continues to influence the development of precision therapeutics.
Previous Service at Lilly
Dr.Carolyn Bertozzi previously served on Eli Lilly’s Board of Directors from 2017 to 2021. During that period, she contributed to shaping the company’s research strategy and strengthening its focus on innovative scientific platforms. Her reappointment signals Lilly’s ongoing interest in integrating leading-edge scientific perspectives into its governance and long-term planning.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical organization that transforms scientific discoveries into medicines aimed at improving health outcomes for people around the world. With nearly 150 years of history, the company has developed therapies that impact millions of patients across diabetes, obesity, Alzheimer’s disease, autoimmune disorders, and oncology. Lilly continues to invest in biotechnology, chemistry, and genetic medicine, while prioritizing inclusive clinical research and efforts to ensure that its therapies are both accessible and affordable.
Eli Lilly’s Becomes Pharma’s First $1 Trillion Company
Written by Nare Hovhannisyan, MD